Sugi Predict

Sugi Predict / Compounds / SCHEMBL436107

SCHEMBL436107

SCHEMBL436107

Cc1cnc(N2CCCC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ GPR119 Q8TDV5 2/20 0.44
▸ DHFR P00374 1/20 0.43
▸ OGA O60502 1/20 0.43
▸ KCNH2 Q12809 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ CNR2 P34972 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085632 0.98 SMN1; SMN2 (0.50) POLBSMN1; SMN2GPR119DHFROGA
SCHEMBL12457554 0.95 GPR119 (0.44) POLBSMN1; SMN2GPR119DHFROGA
SCHEMBL81489 0.84 HRH4 (0.46) POLBDHFROGAALDH1A1TSHR
SCHEMBL18248326 0.82 GPR119 (0.42) POLBSMN1; SMN2GPR119DHFROGA
SCHEMBL81909 0.82 HRH4 (0.51) POLBGPR119DHFROGAALDH1A1
SCHEMBL14853335 0.81 L3MBTL3 (0.50) GPR119KCNH2ALDH1A1
SCHEMBL7991455 0.80 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1TSHR
SCHEMBL6938016 0.80 POLB (0.58) POLBSMN1; SMN2KCNH2ALDH1A1CNR2
SCHEMBL82205 0.80 DHFR (0.44) DHFRALDH1A1
SCHEMBL83122 0.80 OGA (0.50) GPR119DHFROGAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113880859-A 2-aryl-4-arylmethylamino pyrimidine compound and application thereof 江西科技师范大学 2022-01-04 — — CN claimed
WO-2024137329-A1 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2024-06-27 — — WO disclosed
EP-3340983-B1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2023-10-04 — — EP disclosed
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 — — US disclosed
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 — — US disclosed
WO-2023114200-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023114198-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 — — WO disclosed
EP-4129407-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-02-08 — — EP disclosed
CN-113880859-B 2-aryl-4-arylmethylamino pyrimidine compound and application thereof 江西科技师范大学 2022-06-21 — — CN disclosed
US-11273168-B2 Methods of treating anxiety by administering a substituted quinolone OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-03-15 — — US disclosed
US-20110263565-A1 COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 — — US disclosed
US-20110263565-A1 COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 — — US disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 — — US disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 — — US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 — — US disclosed
WO-2010012747-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 — — WO disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 — — US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 — — EP disclosed
US-20070191447-A1 Novel heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 — — US disclosed
US-20070191447-A1 Novel heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11273168-B2 Methods of treating anxiety by administering a substituted quinolone CRH, MC2R, HTR3C POLB 2938/4885SMN1; SMN2 2510/4885GPR119 2367/4885
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 POLB 4386/4885SMN1; SMN2 3023/4885GPR119 1702/4885
US-20070191447-A1 Novel heterocyclic compound OPRD1, GRIN3A, GRM3 POLB 4028/4885SMN1; SMN2 3709/4885GPR119 139/4885
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 POLB 2650/4885SMN1; SMN2 837/4885GPR119 1390/4885
US-20110263565-A1 COMPOUNDS MKI67, CCNA1, CCNT1 POLB 3528/4885SMN1; SMN2 393/4885GPR119 146/4885
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 POLB 4104/4885SMN1; SMN2 3258/4885GPR119 847/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 POLB 3203/4885SMN1; SMN2 4025/4885GPR119 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.